SpeeDx adds Biosapientia to Distribution Network
Partnership with Biosapientia expands SpeeDx product availability in France
SYDNEY, AUSTRALIA – (May 17, 2023). SpeeDx have announced signing a new distribution partner, further extending access for customers to market leading SpeeDx ResistancePlus® and PlexPCR® tests. Biosapientia will distribute SpeeDx ResistancePlus® MG and ResistancePlus® GC tests across the public hospital system, buying groups, and independent private laboratories throughout France.
“We continue to see demand for our key tests and technology around the world,” says Warwick Need, SpeeDx Director of Sales. “Biosapientia are a great fit for SpeeDx products, and we are looking forward to working with them to expand reach into more French laboratories, giving them the opportunity to provide ResistancePlus® tests and support the use of Resistance Guided Therapy (RGT) with their clinician partners.”